AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16738030 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of social identification
Number of subjects: 0
Study 16738030 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher identification
Number of subjects: 0
Study 16738030 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenarios and recollection of personal experiences
Number of subjects: 0
Study 15330959 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC (normal dose = 10-15 microg x kg(‐1) or low dose = 100 microg)
Number of subjects: 125
Study 15330959 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC ND
Number of subjects: 125
Study 15330959 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 125
Study 15330959 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.1 mg x kg(‐1) to 4 mg)
Number of subjects: 125
Study 15330959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 11182214 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet and physical activity counselling based on the stages of change model
Number of subjects: 67
Study 11182214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study 9709727 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant modeling film
Number of subjects: 42
Study 9709727 — intervention group
Group type: COMPARATOR
Intervention: Nonrelevant film
Number of subjects: 42
Study 8291726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 26
Study 8291726 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (control)
Number of subjects: 26
Study 2906898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienoxolol 150 mg
Number of subjects: 6
Study 2906898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienoxolol 300 mg
Number of subjects: 6
Study 2906898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31314967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received HIV testing and counseling, linkage to care, ART (started at a higher CD4 count), and increased access to male circumcision services.
Number of subjects: 12610
Study 31314967 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group received standard care without the enhanced intervention.
Number of subjects: 12610
Study 31314967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group showed a significant increase in the percentage of HIV-positive participants with an HIV-1 RNA level of 400 copies per milliliter or less.
Number of subjects: 12610
Study 31314967 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group showed an increase in the percentage of HIV-positive participants with an HIV-1 RNA level of 400 copies per milliliter or less.
Number of subjects: 12610
Study 31314967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group showed an increase in the percentage of men who underwent circumcision.
Number of subjects: 12610
Study 31314967 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group showed an increase in the percentage of men who underwent circumcision.
Number of subjects: 12610
Study 28904070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1063
Study 28904070 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1063
Study 28904070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1063
Study 25431805 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 26
Study 25431805 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine mouthwash
Number of subjects: 26
Study 24330749 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism intervention with training and support
Number of subjects: 0
Study 24330749 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 24330749 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism intervention
Number of subjects: 0
Study 21554128 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto given at escalating doses over an 18-month period
Number of subjects: 350
Study 21554128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass mailing and advertising recruitment methods
Number of subjects: 350
Study 21554128 — intervention group
Group type: COMPARATOR
Intervention: Comparison with MTOPS participants
Number of subjects: 350
Study 18315429 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg, twice a day for 3 months plus scaling and root planing
Number of subjects: 30
Study 18315429 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules, twice a day for 3 months plus scaling and root planing
Number of subjects: 30
Study 16513078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine (PS) treatment
Number of subjects: 291
Study 11790519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant (TCA)
Number of subjects: 0
Study 11790519 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitor
Number of subjects: 0
Study 11790519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11790519 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment for nonresponders
Number of subjects: 0
Study 10195319 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief counseling (13 sessions over 4 months)
Number of subjects: 28
Study 10195319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 10195319 — intervention group
Group type: EXPERIMENTAL
Intervention: Widows (experimental group)
Number of subjects: 28
Study 10195319 — intervention group
Group type: COMPARATOR
Intervention: Widows (non-experimental group)
Number of subjects: 28
Study 8789577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation (120 mg.day‐1 for 6 weeks)
Number of subjects: 19
Study 8789577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8789577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation
Number of subjects: 19
Study 8789577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone supplementation and exercise
Number of subjects: 19
Study 2405805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating plan with nutritional and behavioral counseling and social support
Number of subjects: 303
Study 2405805 — intervention group
Group type: COMPARATOR
Intervention: Customary diet
Number of subjects: 303
Study 2405805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating plan
Number of subjects: 303
Study 518441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure air environments
Number of subjects: 8
Study 518441 — intervention group
Group type: COMPARATOR
Intervention: Low pressure
Number of subjects: 8
Study 6656327 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care and periodic home visits by nurses or pharmacists
Number of subjects: 171
Study 6656327 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 171
Study 6656327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits and family members monitoring blood pressure and compliance behavior
Number of subjects: 171
Study 6656327 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits alone
Number of subjects: 171
Study 6656327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk characteristics
Number of subjects: 171
Study 31442936 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 216
Study 31442936 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 216
Study 31442936 — intervention group
Group type: EXPERIMENTAL
Intervention: Never institutionalized controls
Number of subjects: 216
Study 30203754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with azithromycin
Number of subjects: 160
Study 26864309 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-Movement Training (FMT)
Number of subjects: 88
Study 24401727 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 40
Study 24401727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22732201 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 180
Study 22732201 — intervention group
Group type: COMPARATOR
Intervention: MPS
Number of subjects: 180
Study 19781120 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan soup (3.5 g/d) for 8 weeks
Number of subjects: 53
Study 19781120 — intervention group
Group type: COMPARATOR
Intervention: Control soup (without beta-glucan) for 8 weeks
Number of subjects: 53
Study 17268215 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Number of subjects: 4278
Study 17268215 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/hydrochlorothiazide 320/25 mg
Number of subjects: 4278
Study 17268215 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/hydrochlorothiazide (combination therapy)
Number of subjects: 4278
Study 17268215 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (incremental doses)
Number of subjects: 4278
Study 17268215 — intervention group
Group type: COMPARATOR
Intervention: valsartan 80 mg
Number of subjects: 4278
Study 15574531 — intervention group
Group type: EXPERIMENTAL
Intervention: Social ecological interventions to promote dual protection
Number of subjects: 48
Study 15574531 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions at structural/environmental, social/interpersonal, and individual levels
Number of subjects: 48
Study 12232492 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 45
Study 12232492 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study 10414570 — intervention group
Group type: EXPERIMENTAL
Intervention: A1-A2 angle in patients with ACoA aneurysms (normoplastic A1 segments)
Number of subjects: 63
Study 10414570 — intervention group
Group type: COMPARATOR
Intervention: A1-A2 angle in control subjects without ACoA aneurysms
Number of subjects: 63
Study 10414570 — intervention group
Group type: EXPERIMENTAL
Intervention: A1-A2 angle associated with ACoA aneurysms
Number of subjects: 63
Study 10414570 — intervention group
Group type: EXPERIMENTAL
Intervention: A1-A2 angle on the non-aneurysm side in patients with ACoA aneurysms
Number of subjects: 63
Study 7477167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (600 mg every 12 hours)
Number of subjects: 84
Study 7477167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (higher-dosage groups)
Number of subjects: 84
Study 7477167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1979634 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker/diuretic combination
Number of subjects: 20
Study 1979634 — intervention group
Group type: COMPARATOR
Intervention: reserpine-containing combination
Number of subjects: 20
Study 7013060 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg per kg body weight)
Number of subjects: 20
Study 7013060 — intervention group
Group type: COMPARATOR
Intervention: No steroids (control group)
Number of subjects: 20
Study 31789486 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment for early DES-ISR
Number of subjects: 352
Study 31789486 — intervention group
Group type: COMPARATOR
Intervention: Drug-coated balloon (DCB) treatment for late DES-ISR
Number of subjects: 352
Study 31163212 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (escitalopram or sertraline) for 12 weeks
Number of subjects: 42
Study 30053031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar saline (1500 mOsm/L)
Number of subjects: 18
Study 30053031 — intervention group
Group type: COMPARATOR
Intervention: Isoosmolar saline (300 mOsm/L)
Number of subjects: 18
Study 27000402 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPsmartER
Number of subjects: 301
Study 27000402 — intervention group
Group type: COMPARATOR
Intervention: MoveMore
Number of subjects: 301
Study 24440015 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT) + percutaneous coronary intervention (PCI)
Number of subjects: 621
Study 24440015 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 621
Study 24440015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic burden
Number of subjects: 621
Study 24440015 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anatomic and ischemic burden
Number of subjects: 621
Study 22878257 — intervention group
Group type: EXPERIMENTAL
Intervention: The11 injury prevention programme (performed in each practice session during one soccer season)
Number of subjects: 456
Study 22878257 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued practice sessions as usual)
Number of subjects: 456
Study 22878257 — intervention group
Group type: EXPERIMENTAL
Intervention: The11 injury prevention programme
Number of subjects: 456
Study 22878257 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 456
Study 20200420 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine buffer (pH 11.1)
Number of subjects: 2
Study 20200420 — intervention group
Group type: COMPARATOR
Intervention: Water (pH 6.8)
Number of subjects: 2
Study 20200420 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic remineralizing medium
Number of subjects: 2
Study 17533529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid Lead Shield
Number of subjects: 65
Study 17533529 — intervention group
Group type: COMPARATOR
Intervention: No Thyroid Shield
Number of subjects: 65
Study 16135593 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 15
Study 12970667 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer group
Number of subjects: 20
Study 12970667 — intervention group
Group type: COMPARATOR
Intervention: Conventional etching and priming group
Number of subjects: 20
Study 10071526 — intervention group
Group type: COMPARATOR
Intervention: Albuterol aerosol (180 micrograms)
Number of subjects: 0
Study 10071526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10071526 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol powder (25 micrograms)
Number of subjects: 0
Study 10071526 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol powder (50 micrograms)
Number of subjects: 0
Study 7482103 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage
Number of subjects: 27
Study 7482103 — intervention group
Group type: COMPARATOR
Intervention: Needle aspiration
Number of subjects: 27
Study 2405200 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 113
Study 2405200 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal approach
Number of subjects: 113
Study 2405200 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal and Retroperitoneal approaches (compared to retrospective data)
Number of subjects: 113
Study 6795049 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 22
Study 6795049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid plus glucose infusion
Number of subjects: 22
Study 6795049 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 31629615 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway‐ Problem based Learning (CP‐PBL)
Number of subjects: 106
Study 31629615 — intervention group
Group type: COMPARATOR
Intervention: Lecture based Learning (LBL) only
Number of subjects: 106
Study 30215723 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202
Study 30215723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study 30215723 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202
Study 30215723 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 202
Study 26935876 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg)
Number of subjects: 650
Study 26935876 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg)
Number of subjects: 650
Study 26935876 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line vonoprazan-based triple therapy (with amoxicillin 750 mg and metronidazole 250 mg)
Number of subjects: 650
Study 24662210 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched treatment (trunk stabilization exercise)
Number of subjects: 124
Study 24662210 — intervention group
Group type: COMPARATOR
Intervention: Unmatched treatment (Movement System Impairment‐directed exercises)
Number of subjects: 124
Study 22257523 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with trastuzumab (ECH-TH group)
Number of subjects: 620
Study 22257523 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with lapatinib (ECL-TL group)
Number of subjects: 620
Study 18829075 — intervention group
Group type: EXPERIMENTAL
Intervention: Single apical injection of 5 mL lidocaine
Number of subjects: 117
Study 18829075 — intervention group
Group type: COMPARATOR
Intervention: Bilateral basal injection of 2 injections of 5 mL lidocaine
Number of subjects: 117
Study 17761060 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 738
Study 17761060 — intervention group
Group type: COMPARATOR
Intervention: Written feedback
Number of subjects: 738
Study 15040542 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/ritonavir (LPV/r) in combination with other antiretroviral agents
Number of subjects: 22
Study 15040542 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/ritonavir (LPV/r)
Number of subjects: 22
Study 12238823 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump beating heart valvular operations using retrograde coronary sinus perfusion
Number of subjects: 50
Study 12238823 — intervention group
Group type: COMPARATOR
Intervention: Conventional valvular operation using retrograde continuous warm blood cardioplegia
Number of subjects: 50
Study 9730852 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1 (3 times a day before meals)
Number of subjects: 6
Study 9730852 — intervention group
Group type: COMPARATOR
Intervention: Saline (3 times a day before meals)
Number of subjects: 6
Study 9730852 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GLP-1
Number of subjects: 6
Study 7914733 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (6 g/day)
Number of subjects: 20
Study 7914733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3197094 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 10
Study 3197094 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 10
Study 3197094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29587655 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg levobupivacaine combined with fentanyl (GL6)
Number of subjects: 62
Study 29587655 — intervention group
Group type: COMPARATOR
Intervention: 8 mg levobupivacaine combined with fentanyl (GL8)
Number of subjects: 62
Study 26773672 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing during 5 sessions
Number of subjects: 56
Study 26773672 — intervention group
Group type: COMPARATOR
Intervention: Health-care services (Control)
Number of subjects: 56
Study 24766732 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib at a starting dose of 5-mg twice daily continuously plus pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 of up to six 21-day cycles (arm I)
Number of subjects: 170
Study 24766732 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib on days 2 through 19 of each cycle plus pemetrexed/cisplatin (arm II)
Number of subjects: 170
Study 24766732 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed/cisplatin alone (arm III)
Number of subjects: 170
Study 22823091 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention using a community organizing approach implemented over 3 years
Number of subjects: 0
Study 22823091 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of implementation of the intervention
Number of subjects: 0
Study 22823091 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (control group)
Number of subjects: 0
Study 20003124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of propofol 1.8 mg/kg at a rate of 1200 ml/h
Number of subjects: 16
Study 20003124 — intervention group
Group type: COMPARATOR
Intervention: Infusion of propofol 12 mg/kg/h
Number of subjects: 16
Study 18668408 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 200 microg PM(2.5)/m(3) (DE(200))
Number of subjects: 16
Study 18668408 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 16
Study 18668408 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 100 microg PM(2.5)/m(3) (DE(100))
Number of subjects: 16
Study 16313113 — intervention group
Group type: EXPERIMENTAL
Intervention: SS syrup
Number of subjects: 38
Study 16313113 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (control group)
Number of subjects: 38
Study 12817525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide (1, 5, 7.5, or 10 micrograms)
Number of subjects: 22
Study 10554645 — intervention group
Group type: COMPARATOR
Intervention: 1 x 8 Gy
Number of subjects: 107
Study 10554645 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 x 3 Gy
Number of subjects: 107
Study 8893680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant FSH (40 cycles)
Number of subjects: 22
Study 8893680 — intervention group
Group type: COMPARATOR
Intervention: Low-dose hMG (26 cycles)
Number of subjects: 22
Study 8295364 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 25 micrograms/ml
Number of subjects: 35
Study 8295364 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 50 micrograms/ml
Number of subjects: 35
Study 8295364 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 100 micrograms/ml
Number of subjects: 35